IMUGENE LIMITED - Announcements

3.64%

26.5¢

Market Cap $76.45M

Healthcare Biotechnology

Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing... Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/25	321.45KB	Share
IMU	Prospectus	PRICE SENSITIVE	16/07/25	475.12KB	Share
IMU	Imugene Capital Raising Presentation	PRICE SENSITIVE	16/07/25	3.53MB	Share
IMU	Imugene Completes $22.5M Placement and c.$15M SPP	PRICE SENSITIVE	16/07/25	291.65KB	Share
IMU	Trading Halt	PRICE SENSITIVE	14/07/25	182.13KB	Share
IMU	Two Additional Complete Responses in azer-cel Ph1b trial	PRICE SENSITIVE	14/07/25	299.25KB	Share
IMU	Imugene Receives $5.8m R&D Tax Refund	PRICE SENSITIVE	04/07/25	140.99KB	Share
IMU	Notice of Extraordinary General Meeting/Proxy Form	PRICE SENSITIVE	27/05/25	209.01KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	629.98KB	Share
IMU	Azer-cel Granted FDA Fast Track Designation in Blood Cancer	PRICE SENSITIVE	19/03/25	167.35KB	Share
IMU	S&P DJI Announces March 2025 Quarterly Rebalance	PRICE SENSITIVE	07/03/25	174.42KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/25	1.24MB	Share
IMU	Imugene Granted India Patent for Oncolytic Virotherapy CF33	PRICE SENSITIVE	27/02/25	148.12KB	Share
IMU	Imugene OnCARlytics Patent Allowance in China	PRICE SENSITIVE	26/02/25	139.63KB	Share
IMU	Azer-cel demonstrates two additional Complete Responses	PRICE SENSITIVE	14/02/25	284.4KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/25	422.97KB	Share
IMU	Imugene Receives A$20 million for Convertible Notes Issuance	PRICE SENSITIVE	29/01/25	142.24KB	Share
IMU	Imugene Receives $11.7m R&D Tax Refund	PRICE SENSITIVE	10/01/25	138KB	Share
IMU	First Australian Patient Dosed in Phase 1b azer-cel Trial	PRICE SENSITIVE	03/01/25	166.55KB	Share
IMU	Issuance of Convertible Notes & Warrants for up to $46m	PRICE SENSITIVE	23/12/24	282.37KB	Share
IMU	Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund	PRICE SENSITIVE	19/12/24	143.5KB	Share
IMU	onCARlytics Trial Doses First Patient in IT Combination Arm	PRICE SENSITIVE	11/11/24	189.72KB	Share
IMU	Imugene Opens First Australian Site for azer-cel Trial	PRICE SENSITIVE	08/11/24	214.26KB	Share
IMU	Complete Response in MAST Study Maintained Over Two Years	PRICE SENSITIVE	05/11/24	191.62KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	461.53KB	Share
IMU	Imugene Receives Orphan Drug Designation for VAXINIA	PRICE SENSITIVE	18/09/24	237.05KB	Share
IMU	Three Complete Responses in Azer-Cel Phase 1b Trial	PRICE SENSITIVE	02/09/24	319.48KB	Share
IMU	Appendix 4E and Annual Report	PRICE SENSITIVE	30/08/24	5.58MB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/24	458.91KB	Share
IMU	First patient dosed in Phase 1 bile tract cancer trial	PRICE SENSITIVE	10/07/24	368.53KB	Share
IMU	Imugene onCARlytics Doses First Patient in IV Combination	PRICE SENSITIVE	24/06/24	169.93KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/24	484.57KB	Share
IMU	Imugene and Kincell Bio Announce Strategic Partnership	PRICE SENSITIVE	16/04/24	220.02KB	Share
IMU	Bile Tract Cancer Study Opens after MAST High Dose Clearance	PRICE SENSITIVE	15/04/24	217.25KB	Share
IMU	VAXINIA and HER-Vaxx featured at the AACR Annual Meeting	PRICE SENSITIVE	08/04/24	173.17KB	Share
IMU	Oncolytic Virotherapy CF33 Patent Granted in China	PRICE SENSITIVE	04/04/24	163.48KB	Share
IMU	Imugene to present at 2024 Cholangiocarcinoma Conference	PRICE SENSITIVE	03/04/24	161.29KB	Share
IMU	Phase 1 onCARlytics Trial Advances to Combination Arm	PRICE SENSITIVE	11/03/24	193.84KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	29/02/24	1.15MB	Share
IMU	Phase 1 onCARlytics Trial Doses First Intravenous Patient	PRICE SENSITIVE	15/02/24	192.99KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	488.54KB	Share
IMU	VAXINIA Phase 1 trial doses patients in higher dose cohorts	PRICE SENSITIVE	19/01/24	239.95KB	Share
IMU	Phase 1 CF33-hNIS Study Update - Positive Early Signals	PRICE SENSITIVE	17/01/24	181.6KB	Share
IMU	Imugene and NeoImmuneTech to Improve Cancer Treatments	PRICE SENSITIVE	12/12/23	193KB	Share
IMU	New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS	PRICE SENSITIVE	06/12/23	176.65KB	Share
IMU	Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine	PRICE SENSITIVE	06/12/23	127.27KB	Share
IMU	FDA Fast Track Designation Granted for VAXINIA Trial Program	PRICE SENSITIVE	28/11/23	161.6KB	Share
IMU	Azer-cel Hits Major Milestone in Phase 1b CAR T Trial	PRICE SENSITIVE	10/11/23	193.03KB	Share
IMU	Phase 1 CF33 VAXINIA Study Update - Positive Early Signals	PRICE SENSITIVE	06/11/23	179.05KB	Share
IMU	Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study	PRICE SENSITIVE	02/11/23	174.52KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/23	488.42KB	Share
IMU	Imugene Phase 1 onCARlytics CD19 virus clinical trial opens	PRICE SENSITIVE	26/10/23	148.52KB	Share
IMU	Imugene B Cell & OV Platforms Featured at ESMO Congress	PRICE SENSITIVE	24/10/23	172.35KB	Share
IMU	Azer-cel FDA IND Transferred to Imugene	PRICE SENSITIVE	28/09/23	148.99KB	Share
IMU	Imugene Closes SPP Raising $18.2 million	PRICE SENSITIVE	25/09/23	118.78KB	Share
IMU	Imugene PD1-Vaxx Update	PRICE SENSITIVE	12/09/23	137.53KB	Share
IMU	Imugene Receives Positive Feedback From FDA	PRICE SENSITIVE	11/09/23	170.25KB	Share
IMU	VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1	PRICE SENSITIVE	04/09/23	156.91KB	Share
IMU	S&P DJI Announces September 2023 Quarterly Rebalance	PRICE SENSITIVE	01/09/23	121.59KB	Share
IMU	Prospectus	PRICE SENSITIVE	25/08/23	665.61KB	Share
IMU	Preliminary Final Report	PRICE SENSITIVE	25/08/23	2.27MB	Share
IMU	Imugene Capital Raising Presentation	PRICE SENSITIVE	18/08/23	2.05MB	Share
IMU	Imugene completes $35M Placement & Launches c.$30M SPP	PRICE SENSITIVE	18/08/23	267.71KB	Share
IMU	Imugene Licenses Allogeneic CD19 CAR T Cell Therapy	PRICE SENSITIVE	16/08/23	178.46KB	Share
IMU	Trading Halt	PRICE SENSITIVE	16/08/23	211.29KB	Share
IMU	Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy	PRICE SENSITIVE	14/08/23	193.5KB	Share
IMU	Imugene CF33 Oncolytic Virus Study to be Showcased at SITC	PRICE SENSITIVE	03/08/23	134.84KB	Share
IMU	Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO	PRICE SENSITIVE	24/07/23	142.89KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	21/07/23	1.4MB	Share
IMU	Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration	PRICE SENSITIVE	20/07/23	250.08KB	Share
IMU	Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US	PRICE SENSITIVE	19/07/23	148.79KB	Share
IMU	New Dose Escalation in Phase I Clinical Trial of CHECKvacc	PRICE SENSITIVE	07/07/23	135.06KB	Share
IMU	HER-Vaxx induced antibodies correlated with tumour reduction	PRICE SENSITIVE	30/06/23	145.8KB	Share
IMU	Imugene PD1-Vaxx patent extended to 2040	PRICE SENSITIVE	29/06/23	119.39KB	Share
IMU	Imugene Advances VAXINIA MAST Trial to Next IV Cohorts	PRICE SENSITIVE	09/06/23	164.13KB	Share
IMU	Imugene doses first combination patient in PD1-Vaxx trial	PRICE SENSITIVE	01/06/23	150.45KB	Share
IMU	FDA clears Imugene IND for onCARlytics first-in-class study	PRICE SENSITIVE	19/05/23	285.34KB	Share
IMU	onCARlytics with ARTEMIS T cells show anti-tumour activity	PRICE SENSITIVE	18/05/23	135.87KB	Share
IMU	onCARlytics with Artemis T cells abstract presented at ASGCT	PRICE SENSITIVE	03/05/23	127.55KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/04/23	1.33MB	Share
IMU	Imugene receives $12.6m R&D tax refund	PRICE SENSITIVE	26/04/23	131.8KB	Share
IMU	Imugene Images and Follows CHECKVacc in TNBC Patients	PRICE SENSITIVE	20/04/23	151.57KB	Share
IMU	First patients dosed in IT & IV cohort 3 of VAXINIA trial	PRICE SENSITIVE	05/04/23	499.46KB	Share
IMU	First Patients Dosed in Combination Study of VAXINIA	PRICE SENSITIVE	03/03/23	195.69KB	Share
IMU	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	1.12MB	Share
IMU	Imugene PD1-Vaxx Immunotherapy Patent Granted in the US	PRICE SENSITIVE	10/02/23	126.56KB	Share
IMU	Imugene VAXINIA trial advances to Combination Cohort	PRICE SENSITIVE	02/02/23	194.71KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/01/23	458.7KB	Share
IMU	Imugene Receives Vaxinia Ethics Approval in Australia	PRICE SENSITIVE	09/01/23	202.94KB	Share
IMU	CHECKVacc Data Presented at the 2022 SABC Symposium	PRICE SENSITIVE	09/12/22	252.41KB	Share
IMU	First Patient Dosed in VAXINIA Intravenous Cohort 2	PRICE SENSITIVE	05/12/22	250.44KB	Share
IMU	Positive New HER-Vaxx HERIZON Data Presented at ESMO Asia	PRICE SENSITIVE	05/12/22	209.85KB	Share
IMU	Imugene onCARlytics with Estrella ARTEMIS T Cells SITC	PRICE SENSITIVE	14/11/22	255.3KB	Share
IMU	Dose escalates In Phase I Clinical Trial of New Oncolytic Vi	PRICE SENSITIVE	11/11/22	250.51KB	Share
IMU	Imugene onCARlytics with blinatumomab SITC presentation	PRICE SENSITIVE	11/11/22	244.77KB	Share
IMU	Imugene onCARlytics with Celularity CyCART-19 T Cells SITC	PRICE SENSITIVE	11/11/22	306.65KB	Share
IMU	ALA: Europe Patent granted for iNKT Cell Therapy Platform	PRICE SENSITIVE	07/11/22	150.42KB	Share
IMU	First patient dosed in VAXINIA intratumoral cohort 2	PRICE SENSITIVE	31/10/22	228.66KB	Share
IMU	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/22	608KB	Share
IMU	Preclinical trial of ALA iNKT therapy and IMU onCARlytics	PRICE SENSITIVE	26/09/22	219.23KB	Share

IMU Quarterly Activities/Appendix 4C Cash Flow Report
31/07/25	PRICE SENSITIVE	321.45KB	Share
IMU Prospectus
16/07/25	PRICE SENSITIVE	475.12KB	Share
IMU Imugene Capital Raising Presentation
16/07/25	PRICE SENSITIVE	3.53MB	Share
IMU Imugene Completes $22.5M Placement and c.$15M SPP
16/07/25	PRICE SENSITIVE	291.65KB	Share
IMU Trading Halt
14/07/25	PRICE SENSITIVE	182.13KB	Share
IMU Two Additional Complete Responses in azer-cel Ph1b trial
14/07/25	PRICE SENSITIVE	299.25KB	Share
IMU Imugene Receives $5.8m R&D Tax Refund
04/07/25	PRICE SENSITIVE	140.99KB	Share
IMU Notice of Extraordinary General Meeting/Proxy Form
27/05/25	PRICE SENSITIVE	209.01KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	629.98KB	Share
IMU Azer-cel Granted FDA Fast Track Designation in Blood Cancer
19/03/25	PRICE SENSITIVE	167.35KB	Share
IMU S&P DJI Announces March 2025 Quarterly Rebalance
07/03/25	PRICE SENSITIVE	174.42KB	Share
IMU Half Yearly Report and Accounts
28/02/25	PRICE SENSITIVE	1.24MB	Share
IMU Imugene Granted India Patent for Oncolytic Virotherapy CF33
27/02/25	PRICE SENSITIVE	148.12KB	Share
IMU Imugene OnCARlytics Patent Allowance in China
26/02/25	PRICE SENSITIVE	139.63KB	Share
IMU Azer-cel demonstrates two additional Complete Responses
14/02/25	PRICE SENSITIVE	284.4KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
31/01/25	PRICE SENSITIVE	422.97KB	Share
IMU Imugene Receives A$20 million for Convertible Notes Issuance
29/01/25	PRICE SENSITIVE	142.24KB	Share
IMU Imugene Receives $11.7m R&D Tax Refund
10/01/25	PRICE SENSITIVE	138KB	Share
IMU First Australian Patient Dosed in Phase 1b azer-cel Trial
03/01/25	PRICE SENSITIVE	166.55KB	Share
IMU Issuance of Convertible Notes & Warrants for up to $46m
23/12/24	PRICE SENSITIVE	282.37KB	Share
IMU Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
19/12/24	PRICE SENSITIVE	143.5KB	Share
IMU onCARlytics Trial Doses First Patient in IT Combination Arm
11/11/24	PRICE SENSITIVE	189.72KB	Share
IMU Imugene Opens First Australian Site for azer-cel Trial
08/11/24	PRICE SENSITIVE	214.26KB	Share
IMU Complete Response in MAST Study Maintained Over Two Years
05/11/24	PRICE SENSITIVE	191.62KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	461.53KB	Share
IMU Imugene Receives Orphan Drug Designation for VAXINIA
18/09/24	PRICE SENSITIVE	237.05KB	Share
IMU Three Complete Responses in Azer-Cel Phase 1b Trial
02/09/24	PRICE SENSITIVE	319.48KB	Share
IMU Appendix 4E and Annual Report
30/08/24	PRICE SENSITIVE	5.58MB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
31/07/24	PRICE SENSITIVE	458.91KB	Share
IMU First patient dosed in Phase 1 bile tract cancer trial
10/07/24	PRICE SENSITIVE	368.53KB	Share
IMU Imugene onCARlytics Doses First Patient in IV Combination
24/06/24	PRICE SENSITIVE	169.93KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
30/04/24	PRICE SENSITIVE	484.57KB	Share
IMU Imugene and Kincell Bio Announce Strategic Partnership
16/04/24	PRICE SENSITIVE	220.02KB	Share
IMU Bile Tract Cancer Study Opens after MAST High Dose Clearance
15/04/24	PRICE SENSITIVE	217.25KB	Share
IMU VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
08/04/24	PRICE SENSITIVE	173.17KB	Share
IMU Oncolytic Virotherapy CF33 Patent Granted in China
04/04/24	PRICE SENSITIVE	163.48KB	Share
IMU Imugene to present at 2024 Cholangiocarcinoma Conference
03/04/24	PRICE SENSITIVE	161.29KB	Share
IMU Phase 1 onCARlytics Trial Advances to Combination Arm
11/03/24	PRICE SENSITIVE	193.84KB	Share
IMU Half Yearly Report and Accounts
29/02/24	PRICE SENSITIVE	1.15MB	Share
IMU Phase 1 onCARlytics Trial Doses First Intravenous Patient
15/02/24	PRICE SENSITIVE	192.99KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	488.54KB	Share
IMU VAXINIA Phase 1 trial doses patients in higher dose cohorts
19/01/24	PRICE SENSITIVE	239.95KB	Share
IMU Phase 1 CF33-hNIS Study Update - Positive Early Signals
17/01/24	PRICE SENSITIVE	181.6KB	Share
IMU Imugene and NeoImmuneTech to Improve Cancer Treatments
12/12/23	PRICE SENSITIVE	193KB	Share
IMU New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS
06/12/23	PRICE SENSITIVE	176.65KB	Share
IMU Europe Patent to be Granted for PD1-Vaxx Cancer Vaccine
06/12/23	PRICE SENSITIVE	127.27KB	Share
IMU FDA Fast Track Designation Granted for VAXINIA Trial Program
28/11/23	PRICE SENSITIVE	161.6KB	Share
IMU Azer-cel Hits Major Milestone in Phase 1b CAR T Trial
10/11/23	PRICE SENSITIVE	193.03KB	Share
IMU Phase 1 CF33 VAXINIA Study Update - Positive Early Signals
06/11/23	PRICE SENSITIVE	179.05KB	Share
IMU Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study
02/11/23	PRICE SENSITIVE	174.52KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
31/10/23	PRICE SENSITIVE	488.42KB	Share
IMU Imugene Phase 1 onCARlytics CD19 virus clinical trial opens
26/10/23	PRICE SENSITIVE	148.52KB	Share
IMU Imugene B Cell & OV Platforms Featured at ESMO Congress
24/10/23	PRICE SENSITIVE	172.35KB	Share
IMU Azer-cel FDA IND Transferred to Imugene
28/09/23	PRICE SENSITIVE	148.99KB	Share
IMU Imugene Closes SPP Raising $18.2 million
25/09/23	PRICE SENSITIVE	118.78KB	Share
IMU Imugene PD1-Vaxx Update
12/09/23	PRICE SENSITIVE	137.53KB	Share
IMU Imugene Receives Positive Feedback From FDA
11/09/23	PRICE SENSITIVE	170.25KB	Share
IMU VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1
04/09/23	PRICE SENSITIVE	156.91KB	Share
IMU S&P DJI Announces September 2023 Quarterly Rebalance
01/09/23	PRICE SENSITIVE	121.59KB	Share
IMU Prospectus
25/08/23	PRICE SENSITIVE	665.61KB	Share
IMU Preliminary Final Report
25/08/23	PRICE SENSITIVE	2.27MB	Share
IMU Imugene Capital Raising Presentation
18/08/23	PRICE SENSITIVE	2.05MB	Share
IMU Imugene completes $35M Placement & Launches c.$30M SPP
18/08/23	PRICE SENSITIVE	267.71KB	Share
IMU Imugene Licenses Allogeneic CD19 CAR T Cell Therapy
16/08/23	PRICE SENSITIVE	178.46KB	Share
IMU Trading Halt
16/08/23	PRICE SENSITIVE	211.29KB	Share
IMU Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy
14/08/23	PRICE SENSITIVE	193.5KB	Share
IMU Imugene CF33 Oncolytic Virus Study to be Showcased at SITC
03/08/23	PRICE SENSITIVE	134.84KB	Share
IMU Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO
24/07/23	PRICE SENSITIVE	142.89KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
21/07/23	PRICE SENSITIVE	1.4MB	Share
IMU Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration
20/07/23	PRICE SENSITIVE	250.08KB	Share
IMU Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US
19/07/23	PRICE SENSITIVE	148.79KB	Share
IMU New Dose Escalation in Phase I Clinical Trial of CHECKvacc
07/07/23	PRICE SENSITIVE	135.06KB	Share
IMU HER-Vaxx induced antibodies correlated with tumour reduction
30/06/23	PRICE SENSITIVE	145.8KB	Share
IMU Imugene PD1-Vaxx patent extended to 2040
29/06/23	PRICE SENSITIVE	119.39KB	Share
IMU Imugene Advances VAXINIA MAST Trial to Next IV Cohorts
09/06/23	PRICE SENSITIVE	164.13KB	Share
IMU Imugene doses first combination patient in PD1-Vaxx trial
01/06/23	PRICE SENSITIVE	150.45KB	Share
IMU FDA clears Imugene IND for onCARlytics first-in-class study
19/05/23	PRICE SENSITIVE	285.34KB	Share
IMU onCARlytics with ARTEMIS T cells show anti-tumour activity
18/05/23	PRICE SENSITIVE	135.87KB	Share
IMU onCARlytics with Artemis T cells abstract presented at ASGCT
03/05/23	PRICE SENSITIVE	127.55KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
28/04/23	PRICE SENSITIVE	1.33MB	Share
IMU Imugene receives $12.6m R&D tax refund
26/04/23	PRICE SENSITIVE	131.8KB	Share
IMU Imugene Images and Follows CHECKVacc in TNBC Patients
20/04/23	PRICE SENSITIVE	151.57KB	Share
IMU First patients dosed in IT & IV cohort 3 of VAXINIA trial
05/04/23	PRICE SENSITIVE	499.46KB	Share
IMU First Patients Dosed in Combination Study of VAXINIA
03/03/23	PRICE SENSITIVE	195.69KB	Share
IMU Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	1.12MB	Share
IMU Imugene PD1-Vaxx Immunotherapy Patent Granted in the US
10/02/23	PRICE SENSITIVE	126.56KB	Share
IMU Imugene VAXINIA trial advances to Combination Cohort
02/02/23	PRICE SENSITIVE	194.71KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
27/01/23	PRICE SENSITIVE	458.7KB	Share
IMU Imugene Receives Vaxinia Ethics Approval in Australia
09/01/23	PRICE SENSITIVE	202.94KB	Share
IMU CHECKVacc Data Presented at the 2022 SABC Symposium
09/12/22	PRICE SENSITIVE	252.41KB	Share
IMU First Patient Dosed in VAXINIA Intravenous Cohort 2
05/12/22	PRICE SENSITIVE	250.44KB	Share
IMU Positive New HER-Vaxx HERIZON Data Presented at ESMO Asia
05/12/22	PRICE SENSITIVE	209.85KB	Share
IMU Imugene onCARlytics with Estrella ARTEMIS T Cells SITC
14/11/22	PRICE SENSITIVE	255.3KB	Share
IMU Dose escalates In Phase I Clinical Trial of New Oncolytic Vi
11/11/22	PRICE SENSITIVE	250.51KB	Share
IMU Imugene onCARlytics with blinatumomab SITC presentation
11/11/22	PRICE SENSITIVE	244.77KB	Share
IMU Imugene onCARlytics with Celularity CyCART-19 T Cells SITC
11/11/22	PRICE SENSITIVE	306.65KB	Share
IMU ALA: Europe Patent granted for iNKT Cell Therapy Platform
07/11/22	PRICE SENSITIVE	150.42KB	Share
IMU First patient dosed in VAXINIA intratumoral cohort 2
31/10/22	PRICE SENSITIVE	228.66KB	Share
IMU Quarterly Activities/Appendix 4C Cash Flow Report
28/10/22	PRICE SENSITIVE	608KB	Share
IMU Preclinical trial of ALA iNKT therapy and IMU onCARlytics
26/09/22	PRICE SENSITIVE	219.23KB	Share

REFRESH

1 2 3

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 26.5¢		Change -0.010(3.64%)		Mkt cap ! $76.45M

Open	High	Low	Value	Volume
27.0¢	27.5¢	26.0¢	$429.4K	1.618M

Buyers (Bids)

No.	Vol.	Price($)
17	433247	26.0¢

Sellers (Offers)

Price($)	Vol.	No.
26.5¢	28052	5

View Market Depth

No.	Vol.	Price($)
16	429401	0.260
18	332553	0.255
29	560028	0.250
10	87366	0.245
10	83374	0.240

Price($)	Vol.	No.
0.265	26303	2
0.270	23003	2
0.275	305890	9
0.280	122485	6
0.285	172137	7

Last trade - 16.10pm 08/08/2025 (20 minute delay)

IMU (ASX) Chart

IMUGENE LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available